Ronald C. Chen, MD, MPH, FASCO, on High-Risk Muscle-Invasive Urothelial Carcinoma: HRQoL With Pembrolizumab vs Observation
ASCO 2026
Ronald C. Chen, MD, MPH, FASCO, of the University of Kansas Medical Center, presents health-related quality of life (HRQoL) data from the AMBASSADOR trial, which showed that in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, adjuvant pembrolizumab for 1 year approximately doubled disease-free survival, causes fatigue and dyspnea which modestly impacted physical function and ability to perform certain roles (such as work and hobbies), without impact on overall quality of life (Abstract 4513).
The ASCO Post Staff
Christopher A. Barker, MD, of Memorial Sloan Kettering Cancer Center, reviews the results of the RAMPART study, a phase II, multicenter, single-arm clinical trial evaluating response-adapted definitive radiotherapy in combination with cemiplimab-rwlc for locally advanced, unresectable cutaneous squamous cell carcinoma (CSCC) (Abstract 9506).
The ASCO Post Staff
Brian M. Wolpin, MD, MPH, of Dana-Farber Cancer Institute, and Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, describe results from the phase III RASolute 302 trial, which evaluated the RAS(ON) muliselective inhibitor daraxonrasib in previously treated patients with metastatic pancreatic adenocarcinoma (Abstract LBA5).
The ASCO Post Staff
Lillian L. Siu, MD, of Princess Margaret Cancer Centre, discusses the clinical utility of liquid biopsy testing for common KRAS variants to facilitate matching patients with pancreatic ductal adenocarcinoma to appropriate early-phase trials (Abstract 3049).
The ASCO Post Staff
Atish Choudhury, MD, PhD, of Dana-Farber Cancer Institute, talks about findings from the phase II A-DREAM/Alliance A032101 trial, which explored the possibility of androgen-deprivation (ADT) interruption in patients with metastatic hormone-sensitive prostate cancer who had an exceptional response to androgen receptor pathway inhibitors (ARPIs) (Abstract 5004).
The ASCO Post Staff
Sanjay Popat, PhD, FRCP, of the Royal Marsden Hospital & Institute of Cancer Research, talks about the findings of the phase III AcceleRET-Lung study, which looked at the oral tyrosine kinase inhibitor pralsetinib as first-line therapy for patients with RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC) (Abstract 8504).
